Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

US (NY): Rules for hemp flower sales approved

New York cannabis regulators approved rules for the state’s cannabinoid hemp program, notably clarifying that flower from the crop can be sold, but delta-8 THC products are currently prohibited from being marketed.

The state Department of Health had initially proposed rules for hemp-derived cannabinoids, and they went through a public comment period before being formally filed by the Office of Cannabis Management (OCM), which was given oversight of the program under the broader cannabis legalization law enacted earlier this year.

Regulators with the Cannabis Control Board (CCB) tackled a number of issues outlining rules for marketing, laboratory testing, labeling, and packaging, but some of the most consequential regulations from a market perspective relate to hemp flower and delta-8 THC, an intoxicating cannabinoid that’s gained popularity and can be synthesized from hemp-derived CBD.

The board also announced that a 60-day public comment period is open for people to weigh in on a draft proposal to allow medical cannabis patients to grow their own plants for therapeutic use. The regulations also mean that OCM will be able to start issuing final licenses for the hemp-derived cannabinoid market. While the rules take effect immediately, businesses will have a six-month window to get into compliance with new testing, packaging, and labeling requirements. 

Read the complete article at marijuanamoment.net

Publication date: